Ozempic Jab’s Creator Needs a Second Act. Pills May Be the Answer. - The New York Times
The New York Times
News & Laws · Evening Edition No. 35 · September 1, 2026
Ozempic Jab’s Creator Needs a Second Act. Pills May Be the Answer. - The New…
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
Medicare Update: Hundreds of Thousands Get GLP-1 Drugs for Just $50
- More than 600,000 Medicare beneficiaries enrolled in the Medicare GLP-1 Bridge program during its first two months after it launched on July 1.
- The program caps patient costs for GLP-1 medications at $50 per month regardless of income level through December 31, 2027.
- Before the new program, patients often faced out-of-pocket expenses exceeding $1,000 per month for GLP-1 medications.
- The program covers select GLP-1 medications including Wegovy, Eli Lilly's Zepbound in its KwikPen form, and Foundayo, an oral GLP-1 treatment.
Newsweek
FDA Approves Mounjaro (Tirzepatide) For Reducing Cardiovascular Risk In Adults With Type 2 Diabetes. Here Are The Best GLP
Forbes
Novo Nordisk stock steadies as Wegovy pill launch in Germany highlights obesity growth - AD HOC NEWS
Novo Nordisk's shares held stable as its Wegovy pill became available in Germany, reflecting wider attention to obesity treatment demand.
- Wegovy pill launched in Germany
- Novo Nordisk stock price remained stable
- Launch points to continued growth in the obesity treatment market
- Report aggregated by Google News from AD HOC NEWS
AD HOC NEWS
Rep. Andy Ogles Blames Ozempic for Jelly Roll’s Trump Comments - Yahoo
Yahoo
The Evening Edition is compiled and published by
GLP-1 Nation,
operated by GLP-1 Studio LLC — a for-profit company founded by the Collective's
Executive Director. Republished here with permission, at no cost. Headlines and
summaries link to the original reporting, which belongs to the publications named.
The Collective pays nothing for this and receives no payment for publishing it.
How this works.